Pfizer will release its fourth-quarter and full-year 2025 financial results Tuesday morning, offering investors the latest look at how the pharmaceutical giant is navigating its post-pandemic reinvention. With COVID-19 product sales now a fraction of their 2022 peak, Pfizer's transformation from pandemic profiteer to diversified drugmaker faces its most important test yet.

Wall Street expects Pfizer to report quarterly revenue of approximately $16.65 billion, down 6.3% year-over-year, reflecting the continued normalization of COVID-related sales. Adjusted earnings per share are projected at $0.57, a figure that would represent meaningful improvement from the company's challenged 2024 results.

The Post-Pandemic Reality

Pfizer's journey from pandemic hero to Wall Street laggard has been swift and humbling. The company's COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid generated combined revenues exceeding $56 billion in 2022, propelling Pfizer to a market capitalization that briefly exceeded $330 billion.

Today, with endemic COVID-19 driving far lower vaccination rates and treatment demand, Pfizer's stock trades roughly 40% below its pandemic-era highs. The company has responded with one of the largest restructuring programs in pharmaceutical industry history.

"We remain on track to deliver about $7.2 billion in total combined net cost savings, with the majority of the savings now expected by the end of 2026 rather than in 2027."

Albert Bourla, CEO, Pfizer

Paxlovid's Uncertain Future

Paxlovid revenues will be a key focus when Pfizer reports. In the most recent comparable period, the COVID-19 treatment generated $727 million, significantly beating analyst expectations of $589 million. However, the trajectory of antiviral demand remains highly uncertain as COVID-19 transitions from pandemic emergency to endemic reality.

Pfizer has guided for COVID-19 product revenues in 2025 to be largely consistent with 2024, excluding approximately $1.2 billion in non-recurring Paxlovid revenue from the prior year. The company has worked to establish Paxlovid as a long-term treatment option, though reimbursement challenges and waning public concern about COVID-19 severity complicate that effort.

Non-COVID Pipeline Holds the Key

Pfizer's future increasingly depends on its non-COVID portfolio, which has shown encouraging momentum. The company's oncology, rare disease, and migraine franchises have delivered solid growth, while strategic acquisitions—including the $43 billion Seagen deal—have bolstered its long-term pipeline.

Analysts will scrutinize progress on key growth drivers including:

  • Oncology: The Seagen acquisition added a portfolio of antibody-drug conjugates with significant commercial potential
  • Rare Diseases: Gene therapy programs and established franchises provide stable revenue streams
  • Migraine: Nurtec/Rimegepant continues gaining market share in a large and growing category
  • RSV Vaccine: Abrysvo launched to competing products, with uptake trends closely watched

2026 Guidance in Focus

Pfizer has already provided full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, with adjusted diluted EPS expected between $2.80 and $3.00. Tuesday's call will offer management's latest thinking on these targets and any potential refinements based on early 2026 trends.

The guidance implies continued contraction from 2025's projected $62 billion revenue, though at a more modest pace than the severe declines experienced in 2023 and 2024. If Pfizer can stabilize its revenue base while delivering cost savings, the stock's current valuation—roughly 9 times forward earnings—could prove attractive.

Investor Positioning

Pfizer shares have gained approximately 4.8% year-to-date heading into the earnings report, modestly outperforming the broader pharmaceutical sector. The average analyst price target of $28.82 implies roughly 9% upside from current levels around $26.37, reflecting cautious optimism about the company's turnaround prospects.

The bull case centers on Pfizer's cost discipline, diversified revenue streams, and potential upside from pipeline programs. Bears counter that the company overpaid for acquisitions during the pandemic windfall and faces years of integration challenges before realizing full value.

Tuesday's report won't resolve that debate, but it will provide crucial evidence for both sides. After years of pandemic-driven volatility, Pfizer is finally approaching the moment when its post-COVID strategy must prove itself—not through promises, but through results.